QLS-111 is under clinical development by Qlaris Bio and currently in Phase II for Ocular Hypertension. According to GlobalData, Phase II drugs for Ocular Hypertension have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how QLS-111’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

QLS-111 overview

QLS-111 is under development for the treatment of normal tension glaucoma, primary open-angle glaucoma, ocular hypertension, and elevated IOP associated with rare diseases such as Sturge-Weber syndrome. The drug candidate is an ATP-sensitive potassium (KATP) channel modulator and is administered through ophthalmic route.

Qlaris Bio overview

Qlaris Bio is a clinical-stage biotechnology company that discovers and develops novel therapeutics targeting ophthalmic diseases. The company’s lead program QLS-111, a novel formulation utilizing our ATP-sensitive potassium (KATP) channel modulator platform, by lowering intraocular pressure (IOP) and relaxing vessels of the vascular and vascular-like tissues distal to the Trabecular Meshwork. It is also investigating EVP-targeted therapies targeting sturge-weber syndrome and normal tension glaucoma. The company is a spinout of Qrativ a biotechnology incubator between Mayo Clinic and Nference. Qlaris Bio is headquartered in Wellesley, Massachusetts, the US.

For a complete picture of QLS-111’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.